Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · IEX Real-Time Price · USD
1.180
+0.130 (12.38%)
May 3, 2024, 4:00 PM EDT - Market closed
XLO's stock price has decreased by -61.69% in the past year and price targets may not have had time to catch up.
Xilio Therapeutics Analyst Ratings
Total Analysts
1
Consensus Rating
Strong Buy
Price Target
$7.00
Upside
+493.22%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +493.22% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +493.22% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +747.46% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +493.22% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,001.69% | Nov 10, 2022 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $32 → $20 | Buy | Maintains | $32 → $20 | +1,594.92% | Aug 10, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +2,950.85% | Jan 10, 2022 |
| Raymond James | Raymond James | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |